Skip to main content

Table 2 Specific clinical characteristics and pharmacological history of the SLE patients

From: First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

 

SLE (n = 66)

Baseline laboratory findings

 Total leukocytes (N cells/mm3, median (IQR))

7.0 (4.5–9.1)

 Total lymphocytes (N cells/mm3, median (IQR))

0.9 (0.5–1.4)

 CD19 positive cells (n = 37) (N cells/mm3/percentage median (IQR))

0.05 (0.03–0.12)/7.0 (4.0–13.0)

 Anti-dsDNA positivity, (n, %)

44 (66.7)

 Low complement levels (n = 61), (n, %)

35 (57.4)

Primary indication for RTX

 Lupus nephritis, n (%)

42 (63.6)

 Neurolupus, n (%)

7 (10.6)

 Lupus related arthritis, n (%)

7 (10.6)

 Mucocutaneous manifestations, n (%)

2 (3.0)

 Haematological manifestations, n (%)

5 (7.6)

 Other manifestationsa, n (%)

3 (4.5)

Ongoing treatment at RTX initiation

 Oral Prednisolone, n (%)

61 (92.4),

 Daily dose, mg (median (IQR))

12.5 (12.5–20.0)

 Antimalarials, n (%)

27 (40.9)

 Azathioprine, n (%)

6 (9.1)

 Mycophenolate, n (%)

9 (13.6)

 Methotrexate, n (%)

3 (4.5)

Previous treatments

 Cyclophosphamide, n (%)

40 (60.6)

 Cumulative dose (median (IQR))

6075 (3150–9275)

 Azathioprine, n (%)

44 (66.7)

 Mycophenolate, n (%)

32 (48.5)

 Methotrexate, n (%)

17 (25.8)

 Cyclosporine A, n (%)

11 (16.7)

  1. IQR Interquartile range, n Number, CD19 Cluster of differentiation 19, anti-dsDNA Anti-double strand-DNA antibodies
  2. aOther manifestation: one fatigue and systemic inflammation, one lung fibrosis, one peripheral polyneuropathy